ACTO
Founded 2014 · 113 employees on LinkedIn · 5 known investors
Acto provides a mobile app platform for field-based sales teams in regulated industries to deliver training, coaching, and presentations with approved content and messaging. The solution includes keyword search, knowledge tracking via surveys, and push notification alerts for content updates.
Also known as Acto · ACTO
Founders & leadership
ACTO was founded in 2014 by Parth Khanna.
Investors · 5
Company profile
researched Aug 2026ACTO develops an "Intelligent Field Excellence" software platform for the life sciences industry, targeting pharmaceutical, biotech and medical device field organizations. The platform combines training, coaching, practice and content delivery for customer-facing roles such as sales representatives and medical science liaisons (MSLs), with the stated aim of improving field readiness, product launches and ongoing brand performance.
The product is organized around three areas. "Educate" covers training modules that break clinical content into short units, gamification for home study and live training, analytics that link learning progress to field performance, and adaptive reinforcement tailored to each user. "Engage" covers AI roleplay for practising HCP conversations with immediate feedback, live and asynchronous manager coaching, field meeting support spanning pre-, live and post-event activity, and messaging tools that let reps personalize approved presentation content and track engagement. "Augment" covers AI workflow agents that automate tasks inside the platform, including role-based AI "SuperAgents" intended to orchestrate work for field teams.
Business model
ACTO sells a software platform to life sciences organizations, with demos requested through its website and login/support portals for existing customers.
Traction
The company states its platform is used by life sciences field professionals across a number of drugs, devices and therapies and product launches, though the figures are not given as specific numbers on the site. Currax Pharmaceuticals' Director of National Sales Training reports that a SuperAgents pilot preceded a full rollout, with faster time to field readiness and improved productivity and retention.
Latest developments
ACTO announced role-based AI SuperAgents purpose-built to orchestrate work for life sciences field teams, described by the company as the first of their kind. CEO Parth Khanna has framed the effort as bringing to the post-approval commercial phase the acceleration AI has brought to drug discovery. Lori Tierney, former President of J&J Vision, is cited endorsing the company's AI direction.
▸Full profile — market position, technology, go-to-market
Market position
ACTO positions itself as a single AI platform covering commercial, medical and launch use cases for life sciences field teams, and states it was the first to introduce role-based AI SuperAgents for this audience. It publishes comparisons of AI roleplay platforms for life sciences field teams, indicating a competitive category around AI-based field training and roleplay.
Technology
The platform applies AI to field enablement workflows, including AI roleplay simulations that give field professionals practice environments with immediate feedback, adaptive learning that adjusts reinforcement to an individual's experience and needs, workflow automation agents, and role-based AI "SuperAgents" designed to orchestrate field team work. Analytics link training progress to field performance measures.
Go-to-market
ACTO markets directly to life sciences enterprises through its website (book-a-demo motion), a resource hub of eBooks, guides, briefs, videos, webinars, events, a blog and a podcast, plus a partner program. Customer testimonials and pilot-to-rollout deployments, such as at Currax Pharmaceuticals, are used as references.
Life sciences companies — pharmaceutical, biotech and medical device firms — and specifically their field-facing functions: sales and commercial excellence, marketing and brand, medical affairs, and commercial learning and development teams.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 4
by search overlap
Companies competing with ACTO for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 1
launches, deals, and filingsACTO announced what it describes as the first role-based AI SuperAgents purpose-built to orchestrate work for life sciences field teams.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 1
primary sources listed
- ACTOacto.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does ACTO do?
- ACTO is an AI-powered field excellence platform that trains, coaches and supports life sciences sales and medical field teams.
- Who founded ACTO?
- ACTO was founded by Parth Khanna in 2014.
- Who are ACTO's investors?
- ACTO's investors include Extreme Venture Partners, Extreme Venture Partners LLP, Good News Ventures, Graphite Ventures, Questa Capital.